Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.

作者信息

Gómez-Randulfe Igor, Califano Raffaele

机构信息

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Division of Cancer Sciences, The University of Manchester, Manchester, UK.

出版信息

Transl Lung Cancer Res. 2023 Aug 30;12(8):1812-1815. doi: 10.21037/tlcr-23-290. Epub 2023 Aug 15.

DOI:10.21037/tlcr-23-290

PMID:37691870

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10483088/

Abstract

摘要

相似文献

[1]

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.

Transl Lung Cancer Res. 2023-8-30

[2]

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Lung Cancer. 2019-7-8

[3]

Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.

JCO Clin Cancer Inform. 2021-1

[4]

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

J Clin Oncol. 2023-4-10

[5]

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.

JTO Clin Res Rep. 2021-7-1

[6]

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.

Int J Cancer. 2021-5-1

[7]

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.

J Thorac Oncol. 2021-10

[8]

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.

J Thorac Oncol. 2021-11

[9]

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.

Cancer. 2020-11-15

[10]

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Lancet Oncol. 2017-7

引用本文的文献

[1]

Persistent lineage plasticity driving lung cancer development and progression.

Clin Transl Med. 2025-8

本文引用的文献

[1]

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

J Clin Oncol. 2023-4-10

[2]

Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.

JAMA Netw Open. 2022-5-2

[3]

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Lancet Oncol. 2021-2

[4]

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).

BMC Cancer. 2020-12-3

[5]

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.

Cancer. 2020-11-15

[6]

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.

N Engl J Med. 2020-8-13

[7]

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.

J Thorac Oncol. 2020-10

[8]

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Ann Oncol. 2019-10-1

[9]

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

PLoS One. 2019-7-31

[10]

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Lancet. 2019-4-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献